We recently contacted all stakeholders for the appraisal of pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of untreated locally advanced non-metastatic triple negative breast cancer [ID1500] regarding a delay to this topic for operational reasons.
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of untreated locally advanced non-metastatic triple negative breast cancer has now been rescheduled into the work programme and the appraisal is due to start late September 2021 and will be discussed at committee in early June 2022.
The new timelines are subject to the work programme capacity and we will continue to review our plans and update our stakeholders accordingly.